189 related articles for article (PubMed ID: 34663404)
1. Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF) in a phase 2 clinical study.
Padilla B; Shields AL; Taylor F; Li X; Mcdonald J; Green T; Boral AL; Lin HM; Akin C; Siebenhaar F; Mar B
Orphanet J Rare Dis; 2021 Oct; 16(1):434. PubMed ID: 34663404
[TBL] [Abstract][Full Text] [Related]
2. Psychometric evaluation of the Advanced Systemic Mastocytosis Symptom Assessment Form (AdvSM-SAF).
Taylor F; Li X; Yip C; Padilla B; Mar B; Green T; Oren R; Boral AL; Lin HM; Shields AL; Gotlib J
Leuk Res; 2021 Sep; 108():106606. PubMed ID: 34004551
[TBL] [Abstract][Full Text] [Related]
3. Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF
Shields AL; Taylor F; Lamoureux RE; Padilla B; Severson K; Green T; Boral AL; Akin C; Siebenhaar F; Mar B
Orphanet J Rare Dis; 2023 Mar; 18(1):69. PubMed ID: 36964624
[TBL] [Abstract][Full Text] [Related]
4. Development of symptom-focused outcome measures for advanced and indolent systemic mastocytosis: the AdvSM-SAF and ISM-SAF
Taylor F; Akin C; Lamoureux RE; Padilla B; Green T; Boral AL; Mazar I; Mar B; Shields AL; Siebenhaar F
Orphanet J Rare Dis; 2021 Oct; 16(1):414. PubMed ID: 34627355
[TBL] [Abstract][Full Text] [Related]
5. Avapritinib versus Placebo in Indolent Systemic Mastocytosis.
Gotlib J; Castells M; Elberink HO; Siebenhaar F; Hartmann K; Broesby-Olsen S; George TI; Panse J; Alvarez-Twose I; Radia DH; Tashi T; Bulai Livideanu C; Sabato V; Heaney M; Van Daele P; Cerquozzi S; Dybedal I; Reiter A; Pongdee T; Barete S; Ustun C; Schwartz L; Ward BR; Schafhausen P; Vadas P; Bose P; DeAngelo DJ; Rein L; Vachhani P; Triggiani M; Bonadonna P; Rafferty M; Butt NM; Oh ST; Wortmann F; Ungerstedt J; Guilarte M; Taparia M; Kuykendall AT; Arana Yi C; Ogbogu P; Gaudy-Marqueste C; Mattsson M; Shomali W; Giannetti MP; Bidollari I; Lin HM; Sulllivan E; Mar B; Scherber R; Roche M; Akin C; Maurer M
NEJM Evid; 2023 Jun; 2(6):EVIDoa2200339. PubMed ID: 38320129
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of lirentelimab in patients with refractory indolent systemic mastocytosis: a first-in-human clinical trial.
Siebenhaar F; Altrichter S; Bonnekoh H; Hawro T; Hawro M; Michaelis EG; Kantor AM; Chang AT; Youngblood BA; Singh B; Rasmussen HS; Maurer M
Br J Dermatol; 2023 Oct; 189(5):511-519. PubMed ID: 37290787
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported disease-specific quality-of-life and symptom severity in systemic mastocytosis.
van Anrooij B; Kluin-Nelemans JC; Safy M; Flokstra-de Blok BM; Oude Elberink JN
Allergy; 2016 Nov; 71(11):1585-1593. PubMed ID: 27089859
[TBL] [Abstract][Full Text] [Related]
8. Psychometric Evaluation of a New Patient-Reported Outcome (PRO) Symptom Diary for Varicose Veins: VVSymQ(®) Instrument.
Wright DD; Paty J; Turner-Bowker DM; Bradbury A
Patient; 2016 Aug; 9(4):335-48. PubMed ID: 27016239
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of the mastocytosis quality of life questionnaire: MC-QoL.
Siebenhaar F; von Tschirnhaus E; Hartmann K; Rabenhorst A; Staubach P; Peveling-Oberhag A; Wagner N; Martus P; Carter MC; Metcalfe DD; Church MK; Maurer M; Weller K
Allergy; 2016 Jun; 71(6):869-77. PubMed ID: 26797792
[TBL] [Abstract][Full Text] [Related]
10. Psychometric evaluation of the Symptoms of Infection with Coronavirus-19 (SIC): results from a cross-sectional study and a phase 3 clinical trial.
Chan EKH; Williams V; Romano C; Fehnel S; Slagle AF; Stoddard J; Sadoff J; Mayorga M; Lewis S; Yarr S; Ma J; Liu Y; Katz EG; McNulty P; van Dromme I; McQuarrie K
J Patient Rep Outcomes; 2023 May; 7(1):45. PubMed ID: 37195456
[TBL] [Abstract][Full Text] [Related]
11. Patient-reported outcomes among patients with systemic mastocytosis in routine clinical practice: Results of the TouchStone SM Patient Survey.
Mesa RA; Sullivan EM; Dubinski D; Carroll B; Slee VM; Jennings SV; Finnerty CC; Bohannon LS; Mathias SD; Lahue BJ; Castells MC
Cancer; 2022 Oct; 128(20):3691-3699. PubMed ID: 35996873
[TBL] [Abstract][Full Text] [Related]
12. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM.
Alvarez-Twose I; Zanotti R; González-de-Olano D; Bonadonna P; Vega A; Matito A; Sánchez-Muñoz L; Morgado JM; Perbellini O; García-Montero A; De Matteis G; Teodósio C; Rossini M; Jara-Acevedo M; Schena D; Mayado A; Zamò A; Mollejo M; Sánchez-López P; Cabañes N; Orfao A; Escribano L; ;
J Allergy Clin Immunol; 2014 Feb; 133(2):520-8. PubMed ID: 23921094
[TBL] [Abstract][Full Text] [Related]
13. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs.
Emanuel RM; Dueck AC; Geyer HL; Kiladjian JJ; Slot S; Zweegman S; te Boekhorst PA; Commandeur S; Schouten HC; Sackmann F; Kerguelen Fuentes A; Hernández-Maraver D; Pahl HL; Griesshammer M; Stegelmann F; Doehner K; Lehmann T; Bonatz K; Reiter A; Boyer F; Etienne G; Ianotto JC; Ranta D; Roy L; Cahn JY; Harrison CN; Radia D; Muxi P; Maldonado N; Besses C; Cervantes F; Johansson PL; Barbui T; Barosi G; Vannucchi AM; Passamonti F; Andreasson B; Ferrari ML; Rambaldi A; Samuelsson J; Birgegard G; Tefferi A; Mesa RA
J Clin Oncol; 2012 Nov; 30(33):4098-103. PubMed ID: 23071245
[TBL] [Abstract][Full Text] [Related]
14. Reliability and validity of simplified Chinese version of Swiss Spinal Stenosis Questionnaire for patients with degenerative lumbar spinal stenosis.
Yi H; Wei X; Zhang W; Chen Z; Wang X; Ji X; Zhu X; Wang F; Xu X; Li Z; Fan J; Wang C; Chen K; Zhang G; Zhao Y; Li M
Spine (Phila Pa 1976); 2014 May; 39(10):820-5. PubMed ID: 24525991
[TBL] [Abstract][Full Text] [Related]
15. Psychometric performance of the Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) in a randomized, double-blind, placebo-controlled crossover study in subjects with mitochondrial disease.
Gwaltney C; Stokes J; Aiudi A; Mazar I; Ollis S; Love E; Karaa A; Houts CR; Wirth RJ; Shields AL
J Patient Rep Outcomes; 2022 Dec; 6(1):129. PubMed ID: 36562873
[TBL] [Abstract][Full Text] [Related]
16. The Number of MRGPRX2-Expressing Cells Is Increased in Skin Lesions of Patients With Indolent Systemic Mastocytosis, But Is Not Linked to Symptom Severity.
Pyatilova P; Ashry T; Luo Y; He J; Bonnekoh H; Jiao Q; Moñino-Romero S; Hu M; Scheffel J; Frischbutter S; Hermans MAW; Youngblood BA; Maurer M; Siebenhaar F; Kolkhir P
Front Immunol; 2022; 13():930945. PubMed ID: 35958589
[TBL] [Abstract][Full Text] [Related]
17. GOunder/Desmoid Tumor Research Foundation DEsmoid Symptom/Impact Scale (GODDESS
Gounder MM; Atkinson TM; Bell T; Daskalopoulou C; Griffiths P; Martindale M; Smith LM; Lim A
Qual Life Res; 2023 Oct; 32(10):2861-2873. PubMed ID: 37347393
[TBL] [Abstract][Full Text] [Related]
18. Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study.
Lortholary O; Chandesris MO; Bulai Livideanu C; Paul C; Guillet G; Jassem E; Niedoszytko M; Barete S; Verstovsek S; Grattan C; Damaj G; Canioni D; Fraitag S; Lhermitte L; Georgin Lavialle S; Frenzel L; Afrin LB; Hanssens K; Agopian J; Gaillard R; Kinet JP; Auclair C; Mansfield C; Moussy A; Dubreuil P; Hermine O
Lancet; 2017 Feb; 389(10069):612-620. PubMed ID: 28069279
[TBL] [Abstract][Full Text] [Related]
19. Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification.
Trizuljak J; Sperr WR; Nekvindová L; Elberink HO; Gleixner KV; Gorska A; Lange M; Hartmann K; Illerhaus A; Bonifacio M; Perkins C; Elena C; Malcovati L; Fortina AB; Shoumariyeh K; Jawhar M; Zanotti R; Bonadonna P; Caroppo F; Zink A; Triggiani M; Parente R; von Bubnoff N; Yavuz AS; Hägglund H; Mattsson M; Panse J; Jäkel N; Kilbertus A; Hermine O; Arock M; Fuchs D; Sabato V; Brockow K; Bretterklieber A; Niedoszytko M; van Anrooij B; Reiter A; Gotlib J; Kluin-Nelemans HC; Mayer J; Doubek M; Valent P
Allergy; 2020 Aug; 75(8):1927-1938. PubMed ID: 32108361
[TBL] [Abstract][Full Text] [Related]
20. Psychometric validation of the Pyruvate Kinase Deficiency Diary and Pyruvate Kinase Deficiency Impact Assessment in adults in the phase 3 ACTIVATE trial.
Andrae DA; Grace RF; Jewett A; Foster B; Klaassen RJ; Salek S; Li J; Tai F; Boscoe AN; Zagadailov E
J Patient Rep Outcomes; 2023 Nov; 7(1):112. PubMed ID: 37943362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
